Microgen

Microgen, established in 2003, is a prominent Russian biotechnology and pharmaceutical company focused on the production of immunobiological products. Operating within the healthcare sector, the company specializes in a diverse portfolio exceeding 250 medical preparations. This extensive range includes critical items such as vaccines, bacteriophages, and immunoglobulins, essential for public health initiatives and medical treatments. Microgen's commitment to advancing medical science is underscored by its pioneering work in developing novel therapies.

The company's operational footprint is substantial, encompassing nine production facilities strategically located across Russia. This distributed manufacturing capability ensures a consistent and reliable supply chain for vital medical supplies nationwide. With an employee base ranging from 1,000 to 5,000 individuals, Microgen possesses the human capital necessary to manage its complex production and research operations. Its annual revenue stands at $57.4M, reflecting its significant market presence and economic contribution within the Russian pharmaceutical landscape.

Microgen has distinguished itself through significant achievements, notably as the developer of the first Russian botulinum toxin type A. The company targets healthcare providers and institutions as its primary clients, supplying them with advanced immunobiological therapies. As a key player in the national healthcare system, Microgen's expertise and product offerings are crucial for disease prevention and treatment. For insights into the individuals driving these advancements, one can Meet Microgen's team. The company also leverages #technology and its #founded_2003 heritage to maintain its leadership position.